Article Details

Everest adds to base camp with $561M biobucks deal for Sinovent-SinoMab's renal disease ...

Retrieved on: 2021-09-17 14:15:00

Tags for this article:

Click the tags to see associated articles and topics

Everest adds to base camp with $561M biobucks deal for Sinovent-SinoMab's renal disease .... View article details on hiswai:

Excerpt

The Shanghai biopharma will dole out $12 million upfront and up to $549 million in biobucks in a licensing agreement with Suzhou Sinovent ...

Article found on: www.fiercebiotech.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up